{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:57:07Z","timestamp":1788184627118,"version":"build-2803163510"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG-25024"],"award-info":[{"award-number":["IG-25024"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ricerca per Credere nella Vita"},{"name":"Progetti di Rilevanza Nazionale PRIN PNRR","award":["P2022PSMX4"],"award-info":[{"award-number":["P2022PSMX4"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"DOI":"10.1186\/s40364-026-00913-3","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T10:29:05Z","timestamp":1775816945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Outcomes of patients with CLL and borderline IGHV mutational status: a systematic review and meta analysis"],"prefix":"10.1186","volume":"14","author":[{"given":"Francesco","family":"Angotzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Bevilacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Serafin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Danesin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Cellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"D\u2019Antiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Pagnin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Frezzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Facco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"Trentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Visentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"issue":"25","key":"913_CR1","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745\u201360.","journal-title":"Blood"},{"issue":"1","key":"913_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/bjh.13940","volume":"173","author":"Z Davis","year":"2016","unstructured":"Davis Z, Forconi F, Parker A, Gardiner A, Thomas P, Catovsky D, et al. The outcome of Chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with <\u200997% identity and similar to those with 98% identity. Br J Haematol. 2016;173(1):127\u201336.","journal-title":"Br J Haematol"},{"issue":"5","key":"913_CR3","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/bjh.16434","volume":"189","author":"S Raponi","year":"2020","unstructured":"Raponi S, Ilari C, Della Starza I, Cappelli LV, Cafforio L, Piciocchi A, et al. Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations. Br J Haematol. 2020;189(5):853\u20139.","journal-title":"Br J Haematol"},{"issue":"6","key":"913_CR4","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3390\/cancers16061095","volume":"16","author":"F Angotzi","year":"2024","unstructured":"Angotzi F, Cellini A, Ruocco V, Cavarretta CA, Zatta I, Serafin A, et al. Chronic Lymphocytic Leukemia (CLL) with Borderline Immunoglobulin Heavy Chain Mutational Status, a Rare Subgroup of CLL with Variable Disease Course. Cancers. 2024;16(6):1095.","journal-title":"Cancers"},{"issue":"3","key":"913_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials"},{"issue":"11","key":"913_CR6","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.3324\/haematol.2019.231027","volume":"105","author":"S Jaramillo","year":"2019","unstructured":"Jaramillo S, Agathangelidis A, Schneider C, Bahlo J, Robrecht S, Tausch E, et al. Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group. Haematologica. 2019;105(11):2598\u2013607.","journal-title":"Haematologica"},{"issue":"3","key":"913_CR7","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/cam4.2788","volume":"9","author":"K Shi","year":"2020","unstructured":"Shi K, Sun Q, Qiao C, Zhu H, Wang L, Wu J, et al. 98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia. Cancer Med. 2020;9(3):999\u20131007.","journal-title":"Cancer Med"},{"key":"913_CR8","doi-asserted-by":"publisher","unstructured":"Morabito F, Shanafelt TD, Gentile M, Reda G, Mauro FR, Rossi D, et al. Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases. American J Hematol [Internet]. 2018 Sep [cited 2025 Jan 18];93(9). Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/ajh.25206","DOI":"10.1002\/ajh.25206"},{"issue":"3","key":"913_CR9","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/bjh.18465","volume":"200","author":"M Kulis","year":"2023","unstructured":"Kulis M, Martin-Subero JI. Integrative epigenomics in chronic lymphocytic leukaemia: Biological insights and clinical applications. Br J Haematol. 2023;200(3):280\u201390.","journal-title":"Br J Haematol"},{"issue":"8","key":"913_CR10","doi-asserted-by":"publisher","first-page":"4320","DOI":"10.1073\/pnas.1913810117","volume":"117","author":"PC Maity","year":"2020","unstructured":"Maity PC, Bilal M, Koning MT, Young M, van Bergen CAM, Renna V, et al. IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling. Proc Natl Acad Sci U S A. 2020;117(8):4320\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"913_CR11","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1182\/blood.2020008311","volume":"137","author":"F Nadeu","year":"2021","unstructured":"Nadeu F, Royo R, Clot G, Duran-Ferrer M, Navarro A, Mart\u00edn S, et al. IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics. Blood. 2021;137(21):2935\u201346.","journal-title":"Blood"},{"issue":"10","key":"913_CR12","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.3324\/haematol.2022.281869","volume":"108","author":"A L\u00fctge","year":"2023","unstructured":"L\u00fctge A, Lu J, H\u00fcllein J, Walther T, Sellner L, Wu B, et al. Subgroup-specific gene expression profiles and mixed epistasis in chronic lymphocytic leukemia. Haematologica. 2023;108(10):2664\u201376.","journal-title":"Haematologica"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00913-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-026-00913-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00913-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T10:29:06Z","timestamp":1775816946000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40364-026-00913-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["913"],"URL":"https:\/\/doi.org\/10.1186\/s40364-026-00913-3","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics committee approval and informed consent were not required since no individual patient\u2019s data were analyzed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}